Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

193 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Whole-exome sequencing in adult ETP-ALL reveals a high rate of DNMT3A mutations.
Neumann M, Heesch S, Schlee C, Schwartz S, Gökbuget N, Hoelzer D, Konstandin NP, Ksienzyk B, Vosberg S, Graf A, Krebs S, Blum H, Raff T, Brüggemann M, Hofmann WK, Hecht J, Bohlander SK, Greif PA, Baldus CD. Neumann M, et al. Among authors: bohlander sk. Blood. 2013 Jun 6;121(23):4749-52. doi: 10.1182/blood-2012-11-465138. Epub 2013 Apr 19. Blood. 2013. PMID: 23603912 Free article.
An 86-probe-set gene-expression signature predicts survival in cytogenetically normal acute myeloid leukemia.
Metzeler KH, Hummel M, Bloomfield CD, Spiekermann K, Braess J, Sauerland MC, Heinecke A, Radmacher M, Marcucci G, Whitman SP, Maharry K, Paschka P, Larson RA, Berdel WE, Büchner T, Wörmann B, Mansmann U, Hiddemann W, Bohlander SK, Buske C; Cancer and Leukemia Group B; German AML Cooperative Group. Metzeler KH, et al. Among authors: bohlander sk. Blood. 2008 Nov 15;112(10):4193-201. doi: 10.1182/blood-2008-02-134411. Epub 2008 Aug 20. Blood. 2008. PMID: 18716133 Free PMC article. Clinical Trial.
CBL exon 8/9 mutants activate the FLT3 pathway and cluster in core binding factor/11q deletion acute myeloid leukemia/myelodysplastic syndrome subtypes.
Reindl C, Quentmeier H, Petropoulos K, Greif PA, Benthaus T, Argiropoulos B, Mellert G, Vempati S, Duyster J, Buske C, Bohlander SK, Humphries KR, Hiddemann W, Spiekermann K. Reindl C, et al. Among authors: bohlander sk. Clin Cancer Res. 2009 Apr 1;15(7):2238-47. doi: 10.1158/1078-0432.CCR-08-1325. Epub 2009 Mar 10. Clin Cancer Res. 2009. PMID: 19276253
NPM1 but not FLT3-ITD mutations predict early blast cell clearance and CR rate in patients with normal karyotype AML (NK-AML) or high-risk myelodysplastic syndrome (MDS).
Schneider F, Hoster E, Unterhalt M, Schneider S, Dufour A, Benthaus T, Mellert G, Zellmeier E, Bohlander SK, Feuring-Buske M, Buske C, Braess J, Fritsch S, Heinecke A, Sauerland MC, Berdel WE, Buechner T, Woermann BJ, Hiddemann W, Spiekermann K. Schneider F, et al. Among authors: bohlander sk. Blood. 2009 May 21;113(21):5250-3. doi: 10.1182/blood-2008-09-172668. Epub 2009 Mar 11. Blood. 2009. PMID: 19279329 Free article.
The CALM and CALM/AF10 interactor CATS is a marker for proliferation.
Archangelo LF, Greif PA, Hölzel M, Harasim T, Kremmer E, Przemeck GK, Eick D, Deshpande AJ, Buske C, de Angelis MH, Saad ST, Bohlander SK. Archangelo LF, et al. Among authors: bohlander sk. Mol Oncol. 2008 Dec;2(4):356-67. doi: 10.1016/j.molonc.2008.08.001. Epub 2008 Sep 4. Mol Oncol. 2008. PMID: 19383357 Free PMC article.
193 results